Browse Category

Stock Market News 26 September 2025

IREN Stock Today (Sept 26, 2025): AI Cloud Moonshot Meets Wall Street Reality Check—Is the Rally Just Pausing or Running Out of Fuel?

IREN Stock Today (Sept 26, 2025): AI Cloud Moonshot Meets Wall Street Reality Check—Is the Rally Just Pausing or Running Out of Fuel?

Key facts (as of 14:27 UTC, Sept 26, 2025) The story today (Sept 26, 2025) IREN shares are sharply lower after JPMorgan cut the stock to Underweight, even as it lifted its price target to $24 from $16—a call that implies sizable downside from recent levels following
RIG Stock Meltdown: Transocean’s $381M Share Sale Rocks the Market—Will 13% Dilution Fix the Debt Problem or Set Up a Rebound?

RIG Stock Meltdown: Transocean’s $381M Share Sale Rocks the Market—Will 13% Dilution Fix the Debt Problem or Set Up a Rebound?

Key facts (Sept. 25–26, 2025) What just happened—and why it mattered Timeline (Sept. 24–26): Strategic aim: Management is steering fresh equity toward debt reduction, specifically highlighting the 8.00% notes due 2027. If all base proceeds went against those notes, annual
AMPY Just Popped ~22% in a Day — Is Amplify Energy’s Rally For Real or a Head‑Fake? What the Fresh Data (Sept. 25–26) Really Shows

AMPY Just Popped ~22% in a Day — Is Amplify Energy’s Rally For Real or a Head‑Fake? What the Fresh Data (Sept. 25–26) Really Shows

In‑depth report What actually happened on Sept. 25–26 Price action: AMPY finished Sept. 25 at $5.84 (+21.67%), trading in a wide $5.17–$6.22 intraday range and posting ~13.5M shares in volume (vs. prior day ~0.54M). The step‑function move capped a three‑session
PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

Key facts (25–26 Sept 2025) What happened—and why it mattered UnitedHealthcare coverage win. On Sept. 25, Plus Therapeutics announced that UnitedHealthcare Insurance Company (UNH) granted national coverage for its CNSide® CSF Tumor Cell Enumeration LDT for metastatic CNS cancer, effective
Go toTop